Last reviewed · How we verify

NCT05863247

Ocular Biomarkers for Successful Premium Trifocal Intra-ocular Lenses Implantation

Status unknown Last updated 17 May 2023
What this trial tests

trial testing Patient Reported Outcomes / Biometric data revision in Presbyopia in 154 participants. Status unknown.

Timeline
1 January 2023
Primary endpoint
1 September 2023
1 December 2023

Quick facts

Lead sponsorHospital dos Lusíadas
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment154
Start date1 January 2023
Primary completion1 September 2023
Estimated completion1 December 2023
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

Hospital dos Lusíadas

Who can join

45 and older, any sex, with Presbyopia or Low Vision. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to identify ocular biomarkers that can predict the success of phacoemulsification with bilateral AT LISA try 839MP (Carl Zeiss Meditec AG) implantation to achieve satisfactory post-post-operativly spectacle-free vision. Social, biometric and patient reported outcomes will be evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Presbyopia

Currently open trials in the same condition.

Other Hospital dos Lusíadas trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05863247.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing